Let's talk medical research

When a clinical trial is in danger of not meeting its endpoints, sponsors may consider rescuing the research initiative by bringing a new set of vendors into the mix. With appropriate planning, sponsors can transition to a new team seamlessly, minimize any momentum lost, and ensure that the new vendors are set up for success.

Like clinical trials for medications, devices must go through various testing processes before they can be approved for patients. Medical device trials, however, are typically smaller in scale and require fewer phases.

With 80% of clinical trials failing to meet enrollment timelines and up to 50% of sites enrolling one or no patients at all, there are many opportunities to “rescue” studies. When timelines are at risk, data quality is suspect, and management practices are questionable, a new vendor can be brought in to rescue a study and get it back on track.

Antidote’s new podcast, Talk of the Towne, focuses on the ultimate sweet spot: that special place where science and patients converge. Our host, Rich Towne, was trained in pharmacy and currently works in Clinical Informatics at Antidote. In each episode, Rich welcomes a new guest from an organization with which Antidote is working, and takes an in-depth look at particular therapeutic areas, ...

In our work, we're honored to speak with advocates about their lived experiences, why they participate in research, and how they engage with their communities. Our partners at the Lupus Research Alliance graciously connected us with Carly H., a lupus nephritis advocate from Brooklyn, New York. We were able to chat with Carly over Zoom about her diagnosis story, why it’s so important to have a ...

Patient-centricity is at the heart of the clinical research community. It’s a guiding principle for study design and recruitment efforts that puts the focus on the people at the core of research: volunteers and their loved ones. At Antidote, we think of patient-centricity as letting the patient voice drive how we think about the recruitment component of the clinical trial process. We look at ...

Is there a connection between kidney disease, cardiovascular disease, and diabetes? What’s exciting about upcoming kidney disease clinical trials? Why is diversity in the kidney disease clinical research space so important? We spoke with Michael Spigler, Vice President of Patient Services and Kidney Disease Education at the American Kidney Fund (AKF) to learn more about AKF’s mission, what ...

This is a reprint of an article originally written by Alexandra Mulvey and published on our partner JDRF’s blog. The piece focuses on Anastasia Albanese-O’Neill, Ph.D., ARNP, CDCES’ excitement about this new role and why clinical trials are the only way to find treatments that work.

Celebrating its 13th year, SCOPE Summit took place from February 7-10, 2022 in Orlando, Florida. This year’s summit was hybrid, but with many making the journey to the in-person event, it was a great opportunity to see familiar faces away from the veil of our screens and devices. The work that the clinical research community does is in a state of transition that has been accelerated due to the ...

Patient recruitment is the most expensive and difficult part of a clinical trial, with recruitment costs representing 40% of the total budget.